Nasal compositions and method of use thereof

1. A method of treating a patient with nasal congestion comprising: administering intranasally to a patient a composition comprising a first composition part and a second composition part, whereby the first composition part is in the form of a liquid decongestant, said liquid decongestant comprising from 0.025-0.05% w/w oxymetazoline, followed by administering intranasally to the patient the second composition part, said second composition part comprising hydroxypropylmethylcellulose (HPMC) powder, and wherein the patient is administered the first and second composition parts daily for seven days, followed by no administration of the first and second composition parts for at least seven days.

2. The method according to claim 1 wherein the first composition part is administered as a dose comprising a single puff or squirt.

3. The method according to claim 2 wherein the second composition part is administered as a dose comprising a single puff or squirt.

4. The method according to claim wherein the second composition part includes at least 50% HPMC powder, or wherein the second composition part includes at least 60, 70, 80, 90 or 99% HPMC powder by total weight of the second composition part.

5. The method according to claim wherein the dosage of the second composition part is between 1 mg -10 mg per nostril of a patient, or wherein the dosage of the second composition part is between 2.5 mg -7.5 mg, between 3-7 mg, between 4-6 mg or about 5 mg per nostril of a patient.

6. The method according to claim 1 , wherein said HPMC powder has a viscosity of 10-20 Pas in a 2% aqueous solution at 20° C., or wherein the HPMC powder has a viscosity of 13-17 Pas, 14-16 Pas or 15 Pas.

7. The method according to claim 1 , wherein the second composition part further includes one or more ingredients selected from the group consisting of kali bichromicum, a thickening agent, gum, starch, a disintegrant, sodium glycolate, a crosslinked povidone, a release agent, magnesium stearate, an emulsifying agent, a surfactant, anticaking agents, granulating agents, preservative, colorant, a signalling agent that can provide the patient with a pleasant sensory feedback upon use, and a flavouring agent that can provide the patient with a pleasant sensory feedback upon use.

8. The method according to claim 1 , wherein the second composition part further includes a signalling agent, wherein the signalling agent is one or more agents selected from the group consisting of mint, menthol, spearmint, any mint variety, turmeric, lemon, lime, peppermint, eucalyptus, strawberry, lavender, citrus, and capsaicin.

9. The method according to claim 1 , wherein the second composition part further includes a signalling agent, wherein the signalling agent comprises up to 50% of the second composition part.

10. The method according to claim 1 wherein the first composition part is applied to the patient immediately followed by the second composition part.

11. A method of treating a patient with nasal congestion comprising: administering intranasally to a patient a first composition comprising 0.025-0.05% w/w oxymetazoline followed by administering intranasally to the patient a second composition comprising hydroxypropylmethylcellulose (HPMC) powder, and wherein the patient is administered the first and second compositions daily for seven days, followed by no administration of the first and second compositions for at least seven days, whereby the HPMC powder has a viscosity of 10-20 Pas in a 2% aqueous solution at 20° C., or wherein the HPMC powder has a viscosity of 13-17 Pas, 14-16 Pas or 15 Pas.

12. The method according to claim 11 whereby the second composition is administered less than five minutes after the first composition is administered.

13. The method according to claim 12 whereby the second composition is administered immediately after the first composition is administered.

14. A method of treating a patient with nasal congestion comprising: administering intranasally to a patient a first composition in the form of a liquid decongestant comprising 0.025-0.5% w/w oxymetazoline followed by administering intranasally to the patient a second composition comprising hydroxypropylmethylcellulose (HPMC) powder, and a third composition comprising a corticosteroid; and wherein the patient is administered the first and second compositions daily for seven days, followed by no administration of the first and second compositions for at least seven days.

15. The method according to claim 14 whereby the third composition is administered immediately before, between or after the first and second compositions.

16. The method according to claim 14 whereby the second composition is administered after the first and third compositions.